Interleukin Genetics Announces Conference Call to Discuss First Quarter 2015 Financial Results

WALTHAM, Mass.--()--Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Friday, May 15, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s first quarter 2015 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company’s website at The webcast will be archived following the call at

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic conditions and to manage existing health and wellness through genetics-based insights and actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic risk panel for periodontal disease and tooth loss susceptibility and its Inherent Health® Weight Management Genetic Test that identifies the most effective diet and exercise programs for an individual, based on an individual’s genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Amendments (CLIA). For more information, please visit


Interleukin Genetics:
Argot Partners
Matthew Haines, 212-600-1902
Susie Kim, 212-600-1902

Interleukin Genetics, Inc.